Teva and Samsung Bioepis Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva Pharmaceutical and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S. Teva will obtain rights to ETICOVO upon close and infliximab-abda in Q3 2027. The deal expands Teva's biosimilars portfolio as part of its Pivot to Growth strategy. Samsung Bioepis will retain regulatory and manufacturing responsibilities. Financial terms include an upfront payment and potential milestone payments.

Teva Pharmaceutical (TEVA) signed a deal with Samsung Bioepis to commercialize two FDA-approved biosimilars, ETICOVO and infliximab-abda, in the U.S. Teva will gain rights to ETICOVO at closing and infliximab-abda in Q3 2027, with the transaction expected to close by late 2026. Teva will make payments over three years and potentially additional milestone payments.

Teva Pharmaceutical (TEVA) will gain U.S. rights to two FDA-approved biosimilars: etanercept-ykro by late 2026 and infliximab-abda in Q3 2027. The deal is subject to regulatory approvals and customary conditions. Financial terms were not disclosed.

Teva Pharmaceuticals halted a Phase II trial for emrusolmin (TEV-‘286) to treat multiple system atrophy (MSA) after an interim analysis suggested it would not meet its primary efficacy endpoint. The decision followed a recommendation from the independent data monitoring committee (IDMC), which found a low probability of demonstrating efficacy. No safety concerns were raised. Teva is developing the therapy in collaboration with privately managed biotechnology company MODAG.

Samsung Bioepis (0126Z0) and Teva Pharmaceuticals agreed to commercialize two biosimilars in the U.S. Samsung Bioepis will handle development and supply, while Teva manages sales. The deal is valued at up to $420 million, including upfront and milestone payments. The biosimilars, Renflexis and Eticovo, treat autoimmune diseases and have FDA approval.

Samsung Bioepis and Teva agreed to a $420M deal for U.S. commercialization of two biosimilars (Renflexis, Eticovo) for autoimmune diseases. Samsung handles development and manufacturing, Teva manages sales. The deal includes upfront payments, milestones, and royalties.